🇺🇸 Catapres-TTS-1 in United States

FDA authorised Catapres-TTS-1 on 10 October 1984

Marketing authorisations

FDA — authorised 10 October 1984

  • Application: NDA018891
  • Marketing authorisation holder: LAVIPHARM
  • Status: supplemented

FDA

  • Status: approved

Catapres-TTS-1 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Catapres-TTS-1 approved in United States?

Yes. FDA authorised it on 10 October 1984; FDA has authorised it.

Who is the marketing authorisation holder for Catapres-TTS-1 in United States?

LAVIPHARM holds the US marketing authorisation.